Estrella Immunopharma Stock Current Ratio
| ESLA Stock | 1.37 0.07 4.86% |
Estrella Immunopharma fundamentals help investors to digest information that contributes to Estrella Immunopharma's financial success or failures. It also enables traders to predict the movement of Estrella Stock. The fundamental analysis module provides a way to measure Estrella Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Estrella Immunopharma stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 24.65 | 0.05 |
Estrella | Current Ratio |
Estrella Immunopharma Company Current Ratio Analysis
Estrella Immunopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Estrella Immunopharma Current Ratio | 0.0489 |
Most of Estrella Immunopharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Estrella Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Estrella Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Estrella Immunopharma is extremely important. It helps to project a fair market value of Estrella Stock properly, considering its historical fundamentals such as Current Ratio. Since Estrella Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Estrella Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Estrella Immunopharma's interrelated accounts and indicators.
| -1.0 | -0.99 | 0.68 | 0.68 | 0.68 | ||
| -1.0 | 1.0 | -0.74 | -0.74 | -0.74 | ||
| -0.99 | 1.0 | -0.79 | -0.79 | -0.79 | ||
| 0.68 | -0.74 | -0.79 | 1.0 | 1.0 | ||
| 0.68 | -0.74 | -0.79 | 1.0 | 1.0 | ||
| 0.68 | -0.74 | -0.79 | 1.0 | 1.0 |
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Estrella Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Estrella Immunopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics of similar companies.Estrella Immunopharma is currently under evaluation in current ratio category among its peers.
Estrella Fundamentals
| Return On Equity | -2.78 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 21.87 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 72.06 % | ||||
| Shares Owned By Institutions | 0.55 % | ||||
| Number Of Shares Shorted | 14.56 K | ||||
| Price To Book | 58.56 X | ||||
| EBITDA | (1.57 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 51.99 M | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) | ||||
| Working Capital | 4.27 M | ||||
| Net Asset | 4.45 M |
About Estrella Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Estrella Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Estrella Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Estrella Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out Estrella Immunopharma Piotroski F Score and Estrella Immunopharma Altman Z Score analysis. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.24) | Return On Assets (1.22) | Return On Equity (2.78) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.